Ofatumumab versus Teriflunomide in Multiple Sclerosis.
| Author | |
| Abstract |
:
Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. |
| Year of Publication |
:
2020
|
| Journal |
:
The New England journal of medicine
|
| Volume |
:
383
|
| Issue |
:
6
|
| Number of Pages |
:
546-557
|
| Date Published |
:
2020
|
| ISSN Number |
:
0028-4793
|
| URL |
:
https://www.nejm.org/doi/10.1056/NEJMoa1917246?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
|
| DOI |
:
10.1056/NEJMoa1917246
|
| Short Title |
:
N Engl J Med
|
| Download citation |
